The role of biomarkers as an alternative and completion of the diagnostic and therapeutic pathway in patients with aortic stenosis (RCD code: VIII)
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2016, Vol 2, Issue 7
Abstract
Aortic stenosis (AS) is the most frequent type of valvular heart disease. Clinically, it presents as calcific and congenital AS. Calcific AS is often age dependent and affects 2–7% of people over 65 years of age. Many clinical studies proved high correlation between age and the prevalence of calcific aortic stenosis. According to todays’ knowledge, AS presents not only as simple degenerative disease of the valve, but as an active inflammatory and proliferative process. Better control and evaluation of risk factors might decelerate progression of the disease. It is necessary to increase the knowledge about risk factors and early markers of AS. Echocardiography is the method of choice in the diagnostic course and evaluation of stenosis grade and disease progression, but the role of biomarkers is becoming more and more significant among the clinical evaluation of patients and has been already mentioned in The European Society of Cardiology (ESC) guidelines on the management of valvular heart disease in patients qualified for Aortic Valve Replacement (AVR) with severe, asymptomatic AS, preserved ejection fraction and normal exercise stress test results. The natriuretic peptides level increase at the follow-up measurements is an important co-factor in decision-making. This review article analyses and summarizes the most important research and correlation between calcific aortic valve disease and the biomarkers. The potential clinical implementation of fourteen biomarkers has been reviewed. Echocardiography depends on the operator experience and imaging quality, therefore biomarkers could contribute important information to patients’ diagnosis and follow-up.
Authors and Affiliations
Jakub Podolec, Łukasz Niewiara, Bartłomiej Guzik, Krzysztof Żmudka
Keywords
Related Articles
- EP ID EP245346
- DOI 10.20418/jrcd.vol2no7.218
- Views 82
- Downloads 0
An uncommon cause of right heart failure: primary cardiac pre-B cell acute lymphoblastic leukemia (RCD code: VI-2C.1).
Hematological malignancies are protean in their presentations. Primary cardiac tumors are exceedingly rare, and primary cardiac leukemia presenting as an isolated mass is even rare. Here, we present a case of a young man...
Effusive‐constrictive pericarditis in a patient with end‐stage renal disease
Renal disease, especially end‐stage renal disease, is associated with possible pericardial involvement. We report the case of a 51‐year‐old patient with a history of end‐stage‐renal disease, currently receiving chronic h...
Journal of Rare Cardiovascular Diseases: Your guide to the latest developments in the field – and to your RCD patient management
Dear Readers, Dear Friends and Colleagues, It is a pleasure to deliver at your hand the next (already the fourth!) issue of your quarterly Journal of Rare Cardiovascular Diseases. We are happy that, with your continued s...
Severe aortic regurgitation and pulmonary hypertension in an 18‑year‑old patient after balloon aortic valvuloplasty (RCD code: IV‑5.A2)
Aortic stenosis is the most common form of congenital left ventricle outflow tract obstruction. It may be a life threatening ductal-dependent condition in newborns and necessitating urgent percutaneous balloon aortic val...
Patient with multiple myeloma and suspected cardiac amyloidosis (RCD code: III‑3A.2a)
49 year‑old patient with multiple myeloma diagnosed a year earlier, after a few cycles of chemotherapy was admitted to hospital with heart failure symptoms accompanied by a rapid atrial flutter. Echocardiography revealed...